Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 301–400 of 709
Ibrahim, R., Olagunju, A., Terrani, K. F., Takamatsu, C., Khludenev, G., & William, P. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02172-w · Cited by 8
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Chimura, M., Docherty, K. F., Jhund, P. S., Yang, M., Ono, R., Henderson, A. D., Metra, M., Liu, G., Divanji, P., Heitner, S. B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf706 · Cited by 8
Self-citationCardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
Felker, G. M., Solomon, S. D., Metra, M., McMurray, J. J. V., Díaz, R., Claggett, B. L., Lanfear, D. E., Vandekerckhove, H. J., Biering‐Sørensen, T., Lópes, R. D., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.11.021 · Cited by 8
Self-citationBhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendra, K., Taha, A., Nadarajah, R., et al. (2025) · Heart · doi:10.1136/heartjnl-2025-326045 · Cited by 7
Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials
van der Bijl, M. F., Scholte, N. T. B., van Oortmerssen, J. A. E., van Lennep, J. E. R., Schut, A., Westendorp, I. C. D., van der Boon, R. M. A., Brugts, J. J., Kardys, I., Appelman, Y., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag311 · Cited by 7
Siddiqi, T. J., Butler, J., Coats, A. J. S., Verma, S., Friede, T., Filippatos, G. S., & Anker, S. D. (2023) · Global Cardiology · doi:10.4081/cardio.2023.2 · Cited by 7
Self-citationSingh, M., Babbarwal, A., Pushpakumar, S. B., & Tyagi, S. C. (2025) · Physiological Reports · doi:10.14814/phy2.70146 · Cited by 7
Barrick, S. K., Garg, A., Greenberg, L., Zhang, S., Lin, C., Stitziel, N. O., & Greenberg, M. J. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.01.014 · Cited by 7
Ferrannini, G., Benson, L., Lautsch, D., Dahlström, U., Lund, L. H., Savarese, G., & Carrero, J. J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14613 · Cited by 7
Self-citationSuebsaicharoen, T., Chunekamrai, P., Yingchoncharoen, T., Tansawet, A., Issarawattana, T., Numthavaj, P., & Thakkinstian, A. (2023) · Open Heart · doi:10.1136/openhrt-2023-002364 · Cited by 7
Gigli, M., Verdonschot, J. A. J., García‐Pavía, P., Stolfo, D., Monserrat, L., Prasad, S. K., Mazzanti, A., Asselbergs, F. W., Bauce, B., Charron, P., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70042 · Cited by 7
Self-citationHyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
Murphy, D., & Banerjee, D. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00552-3 · Cited by 7
Mozzini, C., & Pagani, M. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101834 · Cited by 7
DeVore, A. D., Hill, C. L., Thomas, L. E., Albert, N. M., Butler, J., Patterson, J. H., Hernandez, A. F., Williams, F. B., Shen, X., Spertus, J. A., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13709 · Cited by 7
Parlati, A. L. M., Basile, C., & Filardi, P. P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad026 · Cited by 7
Jarjour, M., & Ducharme, A. (2023) · Drugs in Context · doi:10.7573/dic.2023-5-6 · Cited by 7
PhenoFit: a framework for determining computable phenotyping algorithm fitness for purpose and reuse
Wiley, L. K., Rasmussen, L. V., Levinson, R. T., Malinowski, J. R., Manemann, S. M., Wilson, M. P., Chapman, M., Pacheco, J. A., Walunas, T. L., Starren, J. B., et al. (2025) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaf195 · Cited by 7
Batchelor, R., Tie, E. N., Romero, L., Hopper, I., & Kaye, D. M. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.11.001 · Cited by 7
The current and future status of inotropes in heart failure management
Arfaras-Melainis, A., Ventoulis, I., Polyzogopoulou, E., Boultadakis, A., & Parissis, J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2237869 · Cited by 7
Advances in heart failure management
Zamorano, J. L., & Leal, A. G. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.06.001 · Cited by 7
Correcting dilated cardiomyopathy with fibroblast-targeted p38 deficiencyPreprint
Bretherton, R. C., Reichardt, I. M., Zabrecky, K. A., Goldstein, A. J., Bailey, L. R. J., Bugg, D., McMillen, T. S., Kooiker, K. B., Flint, G. V., Martinson, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.23.523684 · Cited by 7
Trivedi, A., Sohn, W. Y., Hsu, C., Jafarinasabian, P., Zhang, H., Hutton, S., Flach, S. D., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1028 · Cited by 7
Self-citationTrivedi, A., Malik, F. I., Jafarinasabian, P., Zhang, H., Flach, S. D., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.987 · Cited by 7
Self-citationCryo-electron microscopy analysis of myosin at work and at rest
McMillan, S. N., & Scarff, C. A. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102391 · Cited by 7
Muretta, J. M., Rajasekaran, D., Blat, Y., Little, S., Myers, M. C., Nair, C., Burdekin, B., Yuen, S., Jimenez, N., Guhathakurta, P., et al. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.06.001 · Cited by 7
Comparative study of binding pocket structure and dynamics in cardiac and skeletal myosin
Antonovic, A. K., Ochala, J., & Fornili, A. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.2942 · Cited by 7
Choi, J. H., Wood, P., Holmes, J. B., Dominic, K. L., dos Remedios, C. G., Campbell, K. S., & Stelzer, J. E. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00252.2024 · Cited by 7
Scott, B. D., Greenberg, L., Squarci, C., Campbell, K. S., & Greenberg, M. J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515786122 · Cited by 7
Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future
Das, B. B. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44109 · Cited by 6
Hussain, A., Rifai, M. A., Mahtta, D., Liu, J., Jain, V., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00900-5 · Cited by 6
Abboud, A., Nguonly, A., Bean, A., Brown, K., Chen, R. F., Dudzinski, D. M., Fiseha, N., Joice, M. G., Kimaiyo, D., Martin, M. R., et al. (2021) · Open Heart · doi:10.1136/openhrt-2021-001704 · Cited by 6
Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists
Pipilas, A. R., Martyn, T., & Lindenfeld, J. M. (2022) · Structural Heart · doi:10.1016/j.shj.2022.100082 · Cited by 6
Ramadan, M. M., Alshawi, A. L., Mostafa, Y. A., Al-Obeid, M. T., & Elmahal, M. (2025) · Cureus · doi:10.7759/cureus.82128 · Cited by 6
Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction
Margaryan, R., Sepehrvand, N., Ouwerkerk, W., Tromp, J., Turgeon, R. D., & Ezekowitz, J. A. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013074 · Cited by 6
Angélico‐Gonçalves, A., Leite, A. R., Neves, J. S., Saraiva, F. A., Brochado, L., Oliveira, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.05.032 · Cited by 6
Self-citationComparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects
Holmes, J. B., & Stelzer, J. E. (2025) · The Journal of General Physiology · doi:10.1085/jgp.202513762 · Cited by 6
Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure
Greenberg, B. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000060 · Cited by 6
Sen, S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89415 · Cited by 6
Heart Failure Without a Reduced Ejection Fraction
Kumar, S., & Psotka, M. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89417 · Cited by 6
Abel, A. A. I., & Clark, A. L. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s294896 · Cited by 6
Pharmacological Treatment of Heart Failure: Recent Advances
Chan, J. C. H., & Siddiqui, A. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x270178231228061314 · Cited by 6
Pharmacological management of heart failure: a patient-centred approach
Fibbi, G., Sato, R., Vatic, M., Genreith, F. P., & von Haehling, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418414 · Cited by 6
Hattori, Y., Hattori, K., Ishii, K., & Kobayashi, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116232 · Cited by 6
Chronic heart failure: the role of di vericiguat
Caminiti, G., Sposato, B., & Volterrani, M. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad056 · Cited by 6
Dębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.01.003 · Cited by 6
Acute heart failure treatment: a light at the end of the tunnel?
Cotter, G., Davison, B. A., Edwards, C., Takagi, K., Solal, A. C., & Mebazaa, A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2116 · Cited by 6
New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach
Manito, N. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.02.006 · Cited by 6
Coronary Artery Disease and Heart Failure
Patel, P. N., Poliner, M. C., Bossone, E., & Baliga, R. R. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.01.003 · Cited by 6
Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?
Yuen, T. L., Gouda, P., Margaryan, R., & Ezekowitz, J. A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00625-x · Cited by 6
Insuffisance cardiaque et diabète : données épidémiologiques, phénotype et impact sur le pronostic
Isnard, R., Legrand, L., & Pousset, F. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.009 · Cited by 6
A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children
Das, B. B. (2024) · Children · doi:10.3390/children11070859 · Cited by 6
Omecamtiv Mecarbil in Systolic Heart Failure. Reply.
Teerlink, J. R., Felker, G. M., & McMurray, J. J. V. (2021) · PubMed · doi:10.1056/nejmc2102893 · Cited by 6
Cryo-EM reveals how cardiomyopathy therapeutic drugs modulate the myosin motors of the heart
Somavarapu, A. K., Ge, J., Yengo, C. M., Craig, R. W., & Padrón, R. (2026) · Science Advances · doi:10.1126/sciadv.aed6472 · Cited by 6
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis
Zhang, K., Ayala, A., Norambuena‐Soto, I., Agnihotri, V., Shu, T., Nenninger, C. H., Wang, Y., Echevarria, B., Aboagye, J., Huang, K. T., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf813 · Cited by 6
Stroke in Heart Failure With Reduced Ejection Fraction
Gallone, G., Savoca, F., Miccoli, D., Böhm, M., Ferrari, G. M. D., Gottlieb, S. S., Lancellotti, P., Lindenfeld, J. M., Saldarriaga, C., Samad, Z. Z., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.12.008 · Cited by 6
Self-citationMurphy, L., Giblin, G. T., Starr, N., Caples, N., Black, R., Halley, C. M., McDonald, K., & Joyce, E. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14024 · Cited by 6
Liu, C., Karabina, A., Meller, A., Bhattacharjee, A., Agostino, C. J., Bowman, G. R., Ruppel, K. M., Spudich, J. A., & Leinwand, L. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315472121 · Cited by 6
van der Meer, P., Rienstra, M., & van Veldhuisen, D. J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac197 · Cited by 6
Jones, M. R., Tran, C., Singh, J., & Dawson, J. (2022) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2022.100023 · Cited by 6
Docherty, K. F., McMurray, J. J. V., Díaz, R., Felker, G. M., Metra, M., Solomon, S. D., Adams, K. F., Böhm, M., Brinkley, D. M., Echeverría, L. E., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.08.020 · Cited by 6
Self-citationNew Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity
Baracchini, N., Capovilla, T. M., Costantino, S., Puttini, F., Salvioni, E., Mattavelli, I., Valenti, M., d'Elia, E., Bertarelli, E., Agostoni, P., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm41919 · Cited by 5
Seferovic, P. M., Polovina, M. M., Milinković, I., Anker, S. D., Rosano, G. M. C., & Coats, A. J. S. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0013 · Cited by 5
Regional Management of Worsening Heart Failure: Rationale and Design of the CHAIN-HF Registry
Shakoor, A., Emans, M. E., van Gent, M. W. F., Hendrix, A., Faber, N., Springeling, T., de Vette, L. C., Manintveld, O. C., Denham, R. N., van de Meerendonk, C. T. U., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14354 · Cited by 5
Filling the gaps in guideline-directed care
Betz, C. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88672 · Cited by 5
Cardiac contractility modulation in heart failure with reduced ejection fraction treatment
Chugunov, I. A., Mareev, Y. V., Fudim, M., Миронова, Н. А., VIu, M., & Davtyan, K. V. (2022) · Kardiologiia · doi:10.18087/cardio.2022.11.n2014 · Cited by 5
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction
Lanfear, D. E., Njoroge, J. N., Adams, K. F., Anand, I. S., Fang, J. C.-T., Ramires, F. J. A., Sliwa, K. S., Badat, A., Burgess, L. J., Gorodeski, E. Z., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.021 · Cited by 5
Self-citationTópicos Emergentes em Insuficiência Cardíaca: Perspectivas Futuras
de Oliveira, M. T., Villacorta, H., Bittencourt, M. I., Barretto, A. C. P., Mesquita, E. T., & Rohde, L. E. P. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201205 · Cited by 5
The Utility of Genome-Wide Association Studies in Inherited Arrhythmias and Cardiomyopathies
Dababneh, S., Ardehali, A., Badesha, J. K., & Laksman, Z. (2025) · Genes · doi:10.3390/genes16121448 · Cited by 5
Abós, C. M., Mojón, D., Rivas‐Lasarte, M., Tornero, L. C. B., Pàmies, J., Solé‐González, E., Fluvià-Brugués, P., Zegrí‐Reiriz, I., López, L., Brossa, V., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.642117 · Cited by 5
Use of Inotropic Agents in Advanced Heart Failure: Pros and Cons
Hansen, B. L., Kristensen, S. L., & Gustafsson, F. (2024) · Cardiology · doi:10.1159/000536373 · Cited by 5
Inotropic Agents: Are We Still in the Middle of Nowhere?
Iorio, A. M., Lucà, F., Pozzi, A., Rao, C. M., Fusco, S. A. D., Colivicchi, F., Grimaldi, M., Oliva, F. G., & Gulizia, M. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133735 · Cited by 5
Home Inotropes in Advanced Heart Failure: A Practical Review
Manca, P., Matassini, M. V., Fazzini, L., Bianco, M., Nora, C. D., Rizzello, V., Carigi, S., Gennaro, L. D., Tinti, M. D., Maria, R. D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197018 · Cited by 5
Omecamtiv mecarbil, a cardiac myosin activator with potential efficacy in heart failure
Kallash, M., Frishman, W. H., & Aronow, W. S. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/205547 · Cited by 5
Application of optical tweezers in cardiovascular research: More than just a measuring tool
Yang, Y., Fu, Z., Zhu, W. M., Hu, H., & Wang, J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.947918 · Cited by 5
Mefford, M. T., Koyama, S. Y., Jesus, J. D., Wei, R. X., Fischer, H. J., Harrison, T. N., Woo, P., & Reynolds, K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023766 · Cited by 5
Madaudo, C., Bromage, D. I., & Cannata, A. N. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2490403 · Cited by 4
Siddiqi, T. J., Butler, J., Coats, A. J. S., Verma, S., Friede, T., Filippatos, G. S., & Anker, S. D. (2023) · Global Cardiology · doi:10.4081/globcardio.2023.2 · Cited by 4
Self-citationCurrent Targets and Future Directions of Positive Inotropes for Heart Failure
Fairuz, S., Wei, A. C., Mraiche, F., & Goh, J. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673262360231018193823 · Cited by 4
Skouri, H. N., Abdin, A., Müllens, W., Bucciarelli‐Ducci, C., Starling, R. C., van der Meer, P., Savarese, G., Gal, T. B., Bayés‐Genís, A., Heymans, S. R. B., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag115 · Cited by 4
Self-citationChronic heart failure with reduced EF: A decade of major pharmacological innovations
Trochu, J. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104219 · Cited by 4
How Omecamtiv Modulates Myosin Motion
Halder, R., & Warshel, A. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00807 · Cited by 4
Hemodynamics in Left-Sided Cardiomyopathies
Monaco, G. D., Amata, F., Battaglia, V., Panico, C., Condorelli, G., & Pinto, G. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512455 · Cited by 4
Yoshino, K., Takahashi, K., Eda, Y., Nishigaki, A., & Kitao, M. (1991) · PubMed · Cited by 4
Warren, P. F. (2009) · ProQuest LLC eBooks · Cited by 4
Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II
Smith, J. D., Brawley, J., Bordenave, K. C., Olsen, R. K., Intasiri, A., Cremo, C. R., & Bell, T. W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115008 · Cited by 4
Defining a Path Toward Improved Heart Failure Care
Desai, N. R., & Clark, K. A. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89418 · Cited by 4
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Chaudhary, A., Alreefi, F., & Aziz, M. (2021) · CJC Open · doi:10.1016/j.cjco.2021.01.006 · Cited by 4
Жиров, И. В., Safronova, N. V., & Tereshchenko, S. N. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4949 · Cited by 4
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2021.11.017 · Cited by 4
Self-citationHeart Failure Hospitalizations Versus Cardiovascular Mortality in Heart Failure Trials
Kaul, S., Siddiqi, T. J., Anker, S. D., & Butler, J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.074 · Cited by 4
Xu, B., Yuan, Y. Y., Gao, L., Wang, Z., Lv, Z., Yu, W. C., Jin, H., Zhen, Z., Zhao, Z., Na, J., et al. (2025) · Children · doi:10.3390/children12070880 · Cited by 4
Cardiopulmonary Exercise Testing in the Age of New Heart Failure Therapies: Still a Powerful Tool?
Bras, P. G., Gonçalves, A. V., Reis, J., Moreira, R. I., Pereira‐da‐Silva, T., Rio, P., Timóteo, A. T., Silva, S., Soares, R. M., & Ferreira, R. C. (2023) · Biomedicines · doi:10.3390/biomedicines11082208 · Cited by 4
Leveraging Biomarkers for Precision Medicine in Heart Failure
Grossman, S. R., & Gaggin, H. K. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.001 · Cited by 4
Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review
Kenyon, C. R., Wyk, L. V., Flom, A. P., Ibrahim, R., Pham, H. N., Lakhdar, S., Iftikhar, M., & Abdelnabi, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020618 · Cited by 4
Genistein improves heart failure with preserved ejection fraction through BNIP3L-mediated mitophagy
Dou, Z., Sun, D., Huang, Q., Li, H., Yuan, L., Zhao, T., Xu, R., Hong, Y., Gao, J., Li, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117680 · Cited by 4
Trivedi, A., Oberoi, R. K., Jafarinasabian, P., Zhang, H., Spring, M., Flach, S. D., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01051-4 · Cited by 4
Self-citationEsteban‐Fernández, A., Bonilla‐Palomas, J. L., Ayesta-López, A., Pérez-Rivera, J.-Á., Muñoz, R. A., Marcos, M. C., Villanueva, P. D., Pinilla, J. M. G., Artaza, J. G., Méndez, C. J., et al. (2024) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2024.101566 · Cited by 4
Lim, H. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-64740-6_7 · Cited by 4
Ferreira, J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.077 · Cited by 4
A Short Review of New Drugs for Heart Failure: Omecamtiv Mecarbil and Vericiguat
Laksono, S., Pratama, A. P., Halomoan, R., & Andra, C. A. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i2-s.5432 · Cited by 4
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.